Jada System
Solution Overview & Benefits
Postpartum hemorrhage (PPH) remains a leading cause of maternal mortality globally. The JADA® System offers a novel approach to managing PPH by utilizing low-level vacuum to stimulate the uterus's natural contraction mechanisms, effectively controlling bleeding.
Key Benefits:
- Rapid Efficacy: Clinical studies have demonstrated that the JADA® System can control bleeding in a median time of three minutes.
- Ease of Use: In nearly every case, investigators rated the device as easy to use.
- Widespread Adoption: The device is available on hemorrhage carts in more than 2,000 hospitals across the United States.
- Cost-Effective: While the initial acquisition cost is higher than some alternatives, studies have shown that the JADA® System can lead to overall cost savings by reducing the need for blood transfusions, intensive care admissions, and extended hospital stays.
History & Development
The JADA® System was developed by Alydia Health, a company focused on preventing maternal morbidity and mortality caused by postpartum hemorrhage. In August 2020, the device received FDA clearance based on the results of the PEARLE IDE study, which demonstrated its safety and effectiveness.
In 2021, Organon, a global healthcare company dedicated to women's health, acquired Alydia Health to expand the reach of the JADA® System and address critical gaps in maternal care worldwide.
Availability
- Available: worldwide
- Price range (USD): contact solution provider
Specifications
- Mechanism of Action: Utilizes low-level vacuum (80 mm Hg ±10 mm Hg, not exceeding 90 mm Hg) to induce physiological uterine contractions.
- Device Composition: Made of soft silicone, featuring an intrauterine loop with vacuum pores, a cervical seal, and a connector for vacuum tubing.
- Usage Duration: The device remains in place for a duration determined by the healthcare provider, based on the patient's condition, but is generally removed after bleeding is controlled.
- Contraindications: Not suitable for patients with ongoing intrauterine pregnancy, untreated uterine rupture, unresolved uterine inversion, current cervical cancer, known uterine anomalies, or current purulent infections of the vagina, cervix, or uterus.
Additional Information
Similar solutions...
Get in Touch!
Get in touch with us by filling out the form or emailing us at contact@techxlab.org.

